Companies: 10,795·Total market cap: $144.5T
Whitehawk Therapeutics Inc

Whitehawk Therapeutics Inc

WHWKNASDAQHealthcare● Active
$4.02
$-0.13(-3.13%)
Market Cap$198798901
P/E Ratio
52W High$5.495
52W Low$1.57
Overview

Whitehawk Therapeutics Inc (WHWK) Stock Overview

Key statistics and deep links to earnings, valuation, revenue, dividends, and more.

FMP · WHWK · as of Jun 9, 2026

Key Statistics

EPS (TTM)whwk eps ttm · whwk earnings per shareEarnings history
PE Ratio (TTM)whwk pe ratio ttm · whwk price to earningsPE Ratio deep dive
Revenue (TTM)whwk revenue ttm · whwk annual revenueFull revenue history
Dividend YieldNo Dividenddoes whwk pay dividends · whwk dividend yieldDividend history
Shares Outstandingwhwk shares outstanding · whwk floatShares outstanding history
Next EarningsTBAwhwk earnings date · whwk next earningsEarnings history

About Whitehawk Therapeutics Inc

CEODavid J. Lennon
IPO DateAug 1, 2017
Employees40
CountryUS

Whitehawk Therapeutics Inc is a biopharmaceutical enterprise currently undergoing clinical trials. This company specializes in crafting highly targeted treatment options for cancers that are identifi…

what is whitehawk therapeutics inc · whwk stock overview · whitehawk therapeutics inc company profile · who is whitehawk therapeutics inc ceo · whwk NASDAQ · whitehawk therapeutics inc headquarters · whitehawk therapeutics inc business segments

About Stock Overview & Key Data

Whitehawk Therapeutics Inc (WHWK) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Aug 1, 2017. As of the latest trading session, WHWK stock price is $4.02, with a market capitalization of $198.8M. The stock has returned — over the past 12 months and — year-to-date.

Frequently Asked Questions

As of the latest trading session, Whitehawk Therapeutics Inc (WHWK) stock price is $4.02. The stock is traded on NASDAQ under the ticker symbol WHWK. The 52-week range is $1.57 – $5.50.

WHWK stock priceWHWK quote todaylive ticker
Data provided by Financial Modeling PrepLast updated: Jun 9, 2026Not investment advice